Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Diseas... (stage antibody is MT293 (formerly D93)al...)

HOME >> BIOLOGY >> TECHNOLOGY

Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings

Date:10/23/2007

stage antibody is MT293 (formerly D93), also known as TRC093, a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age- related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the intended utilization of product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research, discovery of new product candidates, and clinical trials, and partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, the risks associated with regulatory processes, the risks associated with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners for future revenues under the terms of its existing collaboration agreements, and for further pre-clinical and clinical studies, development and commercialization of product candidates. You are urged to consider statements that include the words "appear," "may," "will
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Wisconsin Assembly passes capital investment bill, revised CAPCO program not presented
2. Olympics of biotechnology has international flavor
3. Traffic data firm navigates international business
4. Catalyst International profit exceeds expectations
5. Lack of broadband hamstrings international videoconferencing
6. 30 days to success: Three simple steps to create your own international startup
7. TEKLYNX International announces new RFID software
8. Ruling enforces international trademark electronic filing requirements
9. Eleftheriou to lead Catalyst International
10. Internet trademark war goes international
11. International eyes drawn to Madisons games research

Post Your Comments:

Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Diseas...(stage antibody is MT293 (formerly D93)al...)